How to buy Sorrento Therapeutics (SRNE) shares in Australia

Learn how to easily invest in Sorrento Therapeutics shares.

Sorrento Therapeutics Inc
- $0.04 ( - 0.58%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Sorrento Therapeutics Inc (SRNE) is a leading biotechnology business with stocks listed in the US. It opened the day at US$8.72 after a previous close of US$8.87. During the day the price has varied from a low of USD8.35 to a high of USD8.83. The latest price was USD8.69 (25 minute delay). Sorrento Therapeutics is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Sorrento Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sorrento Therapeutics. Find the share by name or ticker symbol: SRNE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sorrento Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$8.87, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Sorrento Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sorrento Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sorrento Therapeutics stock price (NASDAQ:SRNE)

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therapeutics shares at a glance

Information last updated 2021-07-09.
Previous closeUS$8.87
Change US$-0.18
Change % -2.0293%
Volume 4,256,938
Information last updated 2021-10-16.
52-week rangeUS$6 - US$17.25
50-day moving average US$7.7306
200-day moving average US$8.1025
Target priceUS$26.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-1.175

Where to buy Sorrento Therapeutics stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Sorrento Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sorrento Therapeutics share growth calculator


Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Sorrento Therapeutics shares?

Before you consider Sorrento Therapeutics, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Sorrento Therapeutics price performance over time

Historical closes compared with the last close of $8.69

1 month (2021-09-16) 7.55%
3 months (2021-07-16) 9.58%
6 months (2021-04-16) 16.02%
1 year (2020-10-16) -6.56%
2 years (2019-10-16) 402.31%
3 years (2018-10-16) 136.14%
5 years (2016-10-14) 22.57%

Stocks similar to Sorrento Therapeutics

Sorrento Therapeutics financials

Revenue TTM US$51 million
Gross profit TTM US$-81,294,000
Return on assets TTM -27.49%
Return on equity TTM -244.23%
Profit margin 0%
Book value 0.641
Market capitalisation US$2.1 billion

TTM: trailing 12 months

Shorting Sorrento Therapeutics shares

There are currently 45.7 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 6% up from 43.1 million last month.

There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.

Sorrento Therapeutics's "short interest ratio" (SIR)

Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 4.3 million). Sorrento Therapeutics's SIR currently stands at 10.51. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 10510 shares are currently held short.

However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1705% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 171 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sorrento Therapeutics.

Find out more about how you can short Sorrento Therapeutics stock.

Sorrento Therapeutics share dividends

We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.

Have Sorrento Therapeutics's shares ever split?

Sorrento Therapeutics's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.

Sorrento Therapeutics share price volatility

Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as US$6 up to US$17.25. A popular way to gauge a stock's volatility is its "beta".

SRNE.US volatility(beta: 2.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.4032. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therapeutics overview

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site